Literature DB >> 3384478

Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin.

S F Little1, S H Leppla, E Cora.   

Abstract

Thirty-six monoclonal antibodies to the protective antigen protein of Bacillus anthracis exotoxin have been characterized for affinity, antibody subtype, competitive binding to antigenic regions, and ability to neutralize lethal and edema toxin activities. At least 23 antigenic regions were detected on protective antigen by a blocking, enzyme-linked immunosorbent assay. Two clones, 3B6 and 14B7, competed for a single antigenic region and neutralized the activity of both the lethal toxin in vivo (Fisher 344 rat) and the edema toxin in vitro (CHO cells). These two antibodies blocked the binding of 125I-labeled protective antigen to FRL-103 cells. Our results support the proposal that binding of protective antigen to cell receptors is required for expression of toxicity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3384478      PMCID: PMC259481          DOI: 10.1128/iai.56.7.1807-1813.1988

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  Production of toxin in vitro by Bacillus anthracis and its spearation into two components.

Authors:  C B THORNE; D M MOLNAR; R E STRANGE
Journal:  J Bacteriol       Date:  1960-03       Impact factor: 3.490

2.  Antigenic regions defined by monoclonal antibodies correspond to structural domains of avian lysozyme.

Authors:  S J Smith-Gill; T B Lavoie; C R Mainhart
Journal:  J Immunol       Date:  1984-07       Impact factor: 5.422

3.  Epitopes of human intestinal alkaline phosphatases, defined by monoclonal antibodies.

Authors:  K Ray; J Vockley; H Harris
Journal:  FEBS Lett       Date:  1984-09-03       Impact factor: 4.124

4.  A simple method for ranking the affinities of monoclonal antibodies.

Authors:  V Van Heyningen; D J Brock; S Van Heyningen
Journal:  J Immunol Methods       Date:  1983-08-26       Impact factor: 2.303

5.  Specificities of monoclonal antibodies against the activated delta-endotoxin of Bacillus thuringiensis var. thuringiensis.

Authors:  M Huber-Lukac; P Lüthy; D G Braun
Journal:  Infect Immun       Date:  1983-05       Impact factor: 3.441

6.  Distinction of epitopes by monoclonal antibodies.

Authors:  C Stähli; V Miggiano; J Stocker; T Staehelin; P Häring; B Takács
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

7.  Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells.

Authors:  S H Leppla
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

8.  Purification and properties of in vitro-produced anthrax toxin components.

Authors:  D C Fish; B G Mahlandt; J P Dobbs; R E Lincoln
Journal:  J Bacteriol       Date:  1968-03       Impact factor: 3.490

9.  Production and characterization of monoclonal antibodies to tetanus toxin.

Authors:  A J Sheppard; D Cussell; M Hughes
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

10.  Evidence for plasmid-mediated toxin production in Bacillus anthracis.

Authors:  P Mikesell; B E Ivins; J D Ristroph; T M Dreier
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

View more
  83 in total

1.  Select human anthrax protective antigen epitope-specific antibodies provide protection from lethal toxin challenge.

Authors:  Sherry R Crowe; Linda L Ash; Renata J M Engler; Jimmy D Ballard; John B Harley; A Darise Farris; Judith A James
Journal:  J Infect Dis       Date:  2010-07-15       Impact factor: 5.226

2.  Production and characterization of monoclonal antibodies against the lethal factor component of Bacillus anthracis lethal toxin.

Authors:  S F Little; S H Leppla; A M Friedlander
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

3.  Anthrax vaccination induced anti-lethal factor IgG: fine specificity and neutralizing capacity.

Authors:  Sherry R Crowe; Lori Garman; Renata J M Engler; A Darise Farris; Jimmy D Ballard; John B Harley; Judith A James
Journal:  Vaccine       Date:  2011-03-21       Impact factor: 3.641

4.  Protective antigen and toxin neutralization antibody patterns in anthrax vaccinees undergoing serial plasmapheresis.

Authors:  Phillip R Pittman; Susan F Leitman; Julio G Barrera Oro; Sarah L Norris; Nina M Marano; Manmohan V Ranadive; Bonnie S Sink; Kelly T McKee
Journal:  Clin Diagn Lab Immunol       Date:  2005-06

5.  Characterization of a permissive epitope insertion site in adenovirus hexon.

Authors:  Michael J McConnell; Xavier Danthinne; Michael J Imperiale
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

6.  A monoclonal antibody to Bacillus anthracis protective antigen defines a neutralizing epitope in domain 1.

Authors:  Johanna Rivera; Antonio Nakouzi; Nareen Abboud; Ekaterina Revskaya; David Goldman; R John Collier; Ekaterina Dadachova; Arturo Casadevall
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

7.  Efficacy of ETI-204 monoclonal antibody as an adjunct therapy in a New Zealand white rabbit partial survival model for inhalational anthrax.

Authors:  Bethany Biron; Katie Beck; David Dyer; Marc Mattix; Nancy Twenhafel; Aysegul Nalca
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

8.  Engineering antibody fragments to fold in the absence of disulfide bonds.

Authors:  Min Jeong Seo; Ki Jun Jeong; Clinton E Leysath; Andrew D Ellington; Brent L Iverson; George Georgiou
Journal:  Protein Sci       Date:  2009-02       Impact factor: 6.725

9.  Domain specificity of the human antibody response to Bacillus anthracis protective antigen.

Authors:  Donald C Reason; Anuska Ullal; Justine Liberato; Jinying Sun; Wendy Keitel; Jianhui Zhou
Journal:  Vaccine       Date:  2008-06-02       Impact factor: 3.641

10.  Identification of a surrogate marker for infection in the African green monkey model of inhalation anthrax.

Authors:  Cynthia A Rossi; Melanie Ulrich; Sarah Norris; Douglas S Reed; Louise M Pitt; Elizabeth K Leffel
Journal:  Infect Immun       Date:  2008-10-13       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.